Medication info
Bielpregabalin Capsule 75 mg (Pregabalin)

Bielpregabalin Capsule 75 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
Light Phamtech Co., Ltd.
Appearance
Brownish-red hard capsule with a white or light yellow powder inside.
Packaging
30 capsules/bottle, 100 capsules/bottle
Approval status
Active

MFDS item code 201902438 · Approved 2019.04.19 · Insurance code 690300810

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
Who takes it
Adults · Children
Adult dose
This drug is administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. Because this drug is eliminated primarily by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1) Peripheral neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg daily. Based on individual patient response and tolerability, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 2) Central neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg daily. Based on individual patient response and tolerability, the dose may be increased to 300 mg daily after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: This drug may be administered at an initial dose of 150 mg daily. Based on individual patient response and tolerability, the dose may be increased to 300 mg daily after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg ~ 450 mg daily. The initial dose is 75 mg twice daily (150 mg daily), and may be increased within 1 week to 150 mg twice daily (300 mg daily), based on efficacy and tolerability. For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Clinical studies have also been conducted at a dose of 600 mg daily; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if this drug is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this drug is excreted primarily by the kidneys as unchanged drug. Clearance of this drug is directly affected by creatinine clearance; therefore, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained from the above equation by 0.85. This drug is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after every 4 hours of hemodialysis. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Dosing regimen Initial dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30 -<60 75 300 BID or TID ≥15 -<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as indicated under the dosing regimen. b: Supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Children under 12 years: Administration is not recommended because sufficient safety and efficacy data are not available. Adolescent patients aged 12 ~17 years: Administration is not recommended because sufficient safety and efficacy data are not available.

Ingredients

Manufacturer
Light Phamtech Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • secondary generalized symptoms
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also effective as an adjunctive treatment for partial seizures in patients with epilepsy. Additionally, it helps alleviate symptoms of fibromyalgia. Therefore, it is widely used in the management of nerve-related pain and certain neurological disorders.

How to take

Adult dose

This drug is administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. Because this drug is eliminated primarily by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1) Peripheral neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg daily. Based on individual patient response and tolerability, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 2) Central neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg daily. Based on individual patient response and tolerability, the dose may be increased to 300 mg daily after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: This drug may be administered at an initial dose of 150 mg daily. Based on individual patient response and tolerability, the dose may be increased to 300 mg daily after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg ~ 450 mg daily. The initial dose is 75 mg twice daily (150 mg daily), and may be increased within 1 week to 150 mg twice daily (300 mg daily), based on efficacy and tolerability. For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Clinical studies have also been conducted at a dose of 600 mg daily; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if this drug is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this drug is excreted primarily by the kidneys as unchanged drug. Clearance of this drug is directly affected by creatinine clearance; therefore, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained from the above equation by 0.85. This drug is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after every 4 hours of hemodialysis. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Dosing regimen Initial dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30 -<60 75 300 BID or TID ≥15 -<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as indicated under the dosing regimen. b: Supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Children under 12 years: Administration is not recommended because sufficient safety and efficacy data are not available. Adolescent patients aged 12 ~17 years: Administration is not recommended because sufficient safety and efficacy data are not available.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so it is essential to consult a physician immediately if mood or behavior changes occur during treatment. Patients with hypersensitivity to this medication or with certain genetic conditions like lactose intolerance should not take this drug. Diabetes patients should be careful as weight gain may require dosage adjustments of their blood glucose control medications. If allergic reactions such as angioedema occur, discontinue use immediately and inform healthcare personnel. Elderly patients may experience dizziness or drowsiness when taking this medication and should be cautious of falling risks until accustomed to its effects. Visual disturbances or changes in vision may occur; if these symptoms arise, consult a physician. Sudden discontinuation of this medication can lead to withdrawal symptoms such as insomnia, headaches, nausea, and anxiety, so dosage should be adjusted according to physician’s instructions. There is a risk of drug misuse, so patients with a history of substance abuse should be particularly cautious and monitored for unusual behaviors. Patients with impaired kidney function may require dosage adjustments, and patients with heart failure need careful observation when taking this medication. Using this medication in combination with opioid analgesics may increase the risk of central nervous system depression, so caution should be exercised. This medication can cause respiratory depression, thus requiring consideration of dosage adjustments in patients with respiratory or kidney diseases and in the elderly. In early pregnancy, there may be a risk of fetal malformations; therefore, women who are pregnant or planning to become pregnant should consult a physician and use effective contraception. During breastfeeding, this medication may be excreted in breast milk and could affect the baby, so careful consideration of breastfeeding and medication use is necessary. When engaging in potentially hazardous activities such as driving or operating machines, be cautious as dizziness or drowsiness may occur. Severe skin reactions can rarely occur; if skin rashes, redness, or blisters develop, discontinue use immediately and inform a physician. In case of overdose, symptoms may include confusion, drowsiness, and depression, and emergency treatment such as dialysis may be necessary.

Side effects

Suicidal thoughts, suicidal behaviors, depression, angioedema, facial swelling, edema around the mouth, upper respiratory tract edema, dizziness, drowsiness, loss of consciousness, confusion, mental disorders, blurred vision, changes in vision, insomnia, headache, nausea, anxiety, diarrhea, influenza-like syndrome, restlessness, suicidal thoughts, pain, seizures, perspiration, misuse, abuse, dependence, congestive heart failure, severe respiratory depression, respiratory function decline, rhinitis, neutropenia, increased appetite, decreased appetite, hypoglycemia, confusion, disorientation, irritability, euphoria, decreased libido, depersonalization, sexual dysesthesia, agitation, mood swings, emotional blunting, emotional elevation, hallucinations, abnormal dreams, increased libido, panic attack, impulsivity, apathy, ataxia, abnormal motor coordination, balance disorders, amnesia, attention deficit, memory impairment, tremor, dysarthria, sensory abnormalities, sensory loss, sedation, drowsiness, cognitive impairment, nystagmus, language disorders, dystonic muscle spasms, diminished reflexes, movement abnormalities, psychomotor agitation, positional dizziness, hypersensitivity, burning sensation, tremor at rest, syncope, confusion, hypokinesia, olfactory disturbances, taste loss, writing difficulties, blurred vision, diplopia, indirect vision loss, visual disturbances, visual field loss, photophobia, dry eyes, eyelid swelling, decreased vision, ocular pain, eye fatigue, increased tear production, ocular irritation, mydriasis, during vibration, changes in the depth perception of vision, strabismus, visual brightness, vertigo, hyperacusis, first-degree AV block, tachycardia, homogenous bradycardia, homogenous tachycardia, homogenous arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, pharyngeal tension, nasal dryness, respiratory depression, vomiting, abdominal distension, constipation, dry mouth, bloating, excessive salivation, gastroesophageal reflux, oral sensory loss, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweats, muscle cramps, arthralgia, back pain, limb pain, cervical spasm, joint swelling, myalgia, muscle spasms, neck pain, muscle rigidity, rhabdomyolysis, urinary disorders, urinary incontinence, decreased urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, mastalgia, breast discharge, breast enlargement, peripheral edema, edema, gait abnormalities, falls, feeling drunk, sensory abnormalities, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased serum creatine phosphokinase, increased aspartate aminotransferase, increased blood sugar, decreased platelet count, decreased serum potassium, weight loss, increased serum creatinine, decreased white blood cell count, hypersensitivity, allergic reaction, headache, keratitis, pulmonary edema, nausea, diarrhea, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, delirium, paralysis, affective disorder, drowsiness, confusion state, agitation, restlessness, worsening of convulsions, sleep disorders, bloody stools, tinnitus

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect against air or moisture. Ideal storage temperature is between 15 and 30 degrees Celsius.

Appearance and packaging

Appearance

Brownish-red hard capsule with a white or light yellow powder inside.

Package unit

30 capsules/bottle, 100 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.